Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
about
Proteomic identification of Hsp70 as a new Plk1 substrate in arsenic trioxide-induced mitotically arrested cellsInduction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitorsSmall interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cellsBreast cancer biomarker discovery in the functional genomic age: a systematic review of 42 gene expression signatures.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicPathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.Centrosomal protein 55 (Cep55) stability is negatively regulated by p53 protein through Polo-like kinase 1 (Plk1)PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins.Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with acute myeloid leukemia.Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?Cell-based apoptosis assays in oncology drug discovery.Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer.Antitumoral effect of PLK-1-inhibitor BI2536 in combination with cisplatin and docetaxel in squamous cell carcinoma cell lines of the head and neck.Targeting polo-like kinase 1 in acute myeloid leukemia.Molecular interactions of polo-like kinase 1 in human cancers.Molecular mechanism of anticancer effect of Sclerotium rolfsii lectin in HT29 cells involves differential expression of genes associated with multiple signaling pathways: A microarray analysis.RNA-binding protein RBM8A (Y14) and MAGOH localize to centrosome in human A549 cells.Polo-like kinase 1 inhibition causes decreased proliferation by cell cycle arrest, leading to cell death in glioblastoma.Inhibition of polo-like kinase 1 induces cell cycle arrest and sensitizes glioblastoma cells to ionizing radiation.Antitumor activity of a small-molecule inhibitor of the histone kinase HaspinInduction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.Genetic depletion of Polo-like kinase 1 leads to embryonic lethality due to mitotic aberrancies.Polo-like kinase 1 (Plk1) in cutaneous T-cell lymphoma.Polo-like kinase 1 as target for cancer therapy.Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer.Effect of rosemary polyphenols on human colon cancer cells: transcriptomic profiling and functional enrichment analysis.Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.Volasertib Enhances Sensitivity to TRAIL in Renal Carcinoma Caki Cells through Downregulation of c-FLIP Expression.Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.Linear Regression QSAR Models for Polo-Like Kinase-1 Inhibitors.Mitosis is not a key target of microtubule agents in patient tumors.
P2860
Q24337180-80D750DE-ABEC-450D-BC9C-F6C110D3DC4FQ30538161-825D7A82-BA40-4F88-9563-05A2A66D828BQ33713695-066249DD-BFB4-4A2B-BD70-0B5D9BCE7F75Q34152071-FD5F5E77-8BD8-443D-BE37-6BCD418F445AQ34184864-C7467B8B-B587-44A9-87AE-B76C49509528Q34300700-EB44D726-C414-4311-BBF6-21D3E0B4DAA0Q34817365-C24C2344-0710-4232-919B-06C082E8EE29Q35374477-DA3D72EA-E134-49F2-83B7-C1D7BC353904Q35763224-77736D9E-5848-482B-A988-06629EB14B3EQ35832219-9F2795AB-8BD7-4162-85F4-EA9BF6866261Q36467485-4414DA12-E7B1-4994-8A99-5E3EAADDFAB6Q37833892-FFC4F66E-45D0-47B1-AD75-558B9C8C668AQ37994256-288B7A3C-4867-4716-A99E-B5FFC4F174CBQ38028557-0D65A1D2-3891-4748-B782-4E5656F48457Q38099046-60DCE7AB-8ADC-4324-94FC-71ED1A33808FQ38292744-2470B2B9-8E46-46BF-8647-18F78EE65F1BQ38398864-3A2C701A-7936-43D8-B838-54DCE82615D0Q38760108-AC0FC5A7-3C1A-4A7F-8604-DE2CC7D1BF1CQ38837139-AA3B9818-6541-4C99-9808-5198E581EA52Q39109744-A9E37EC7-5D1D-447F-849F-62D2FB771380Q39120232-F81A8FD6-0411-4204-96A0-72B8F6233F7FQ39146648-AB8458FF-AC2D-4BAA-AAE0-2597AC6D269EQ39497589-E03F5DEF-7E43-4321-94DC-30B2E5C29959Q39547514-15E1DD92-6D36-4DC4-B3C9-D5F1A523755EQ39601527-33C07FF8-4D23-4890-8358-508FD5E844D0Q39633115-E5C0BBCF-3824-4853-A076-5B009E5BF2F4Q41813783-2C051EC7-650E-48B8-A27E-727CAED5C33AQ42088063-EC724A70-9A62-4B9F-B0D2-FD7622EB2A38Q42502767-22665F5F-62E2-4AA1-B85D-5461DCBA3E29Q42689215-34CB9E2A-87FA-494F-BA34-97323011980AQ47352578-C57CEB9D-C475-4A53-9629-20F34E07EA8CQ48231954-2397B3E9-3972-4F33-95BB-CF9F61798A3CQ48875498-E5999A56-BB3E-4ECE-9C15-B14D7BCE6D70Q49379572-3908BF52-A2CC-42DC-8FA3-5F1CCBB09336Q50002325-C7F80201-C34F-40C8-B845-A82073916D7DQ53271035-2F073896-3608-497B-872E-7D9033D6286C
P2860
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
@en
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
@nl
type
label
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
@en
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
@nl
prefLabel
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
@en
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics.
@nl
P2093
P1476
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
@en
P2093
Abhijit Ray
Puneet Chopra
Sunanda G Dastidar
P356
10.1517/13543780903483191
P407
P50
P577
2010-01-01T00:00:00Z